Through all the market madness of the past two years, there has been one truth universally acknowledged by the analysts who ...

XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic benefits through a ...

XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic benefits through a unique fat-blocking mechanism. However, its high ...

For any one with a straining waistband, the next step was once a given: heading to the local church hall for an evening of ...

But this is just the start. GLP-1 drugs (specifically Novo Nordisk’s Ozempic, Rybelsus and Wegovy and Eli Lilly’s Mounjaro ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

To that end, let's consider five excellent growth-oriented companies to invest in on the dip: Novo Nordisk ( NVO -1.69%), Eli ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Study results in a rare form of obesity could help the company expand use of Imcivree, which is approved for two genetically ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

The Trump administration rejected a proposed rule to allow Medicare to cover blockbuster obesity drugs for weight loss alone ...

"First, I eat far less. That seems to be what everyone on Wegovy does. Second, I eat totally different things vs before," ...